[CAS NO. 5995-86-8] Gallic acid hydrate

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [5995-86-8]

Catalog

HY-N0523A

Brand

MCE

CAS

5995-86-8

DESCRIPTION [5995-86-8]

Overview

MDL	MFCD00149098
Molecular Weight	188.13
Molecular Formula	C7H8O6
SMILES	O=C(O)C1=CC(O)=C(O)C(O)=C1.O

For research use only. We do not sell to patients.

6 Publications Citing Use of MCE

Summary

Gallic acid (3,4,5-Trihydroxybenzoic acid) hydrate is a natural polyhydroxyphenolic compound and an free radical scavenger to inhibit cyclooxygenase-2 (COX-2) ^[1] . Gallic acid hydrate has various activities, such as antimicrobial, antioxidant, antimicrobial, anti-inflammatory, and anticance activities ^[2] .

IC50 & Target

Human Endogenous Metabolite

COX-2

Microbial Metabolite

In Vitro

Gallic acid is an antioxidant which can inhibit both COX-2 ^[1] . After 18 h treatment with Gallic acid, the number of viable neutrophils is dramatically decreased from 40.3% to 27.7%, highly comparable with 26.4% for untreated neutrophils. Gallic acid fails to attenuate isoproterenol-induced myocytolysis ^[3] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

The food intake (2.6±0.08 g/day, p=0.69) and the body weight (2.5±0.69 g, p=0.76) of the Gallic acid group do not differ significantly from those of the control group (food intake; 2.41±0.14 g/day and the body weight; 2.83±0.84 g/day). The blood glucose tolerance in the Gallic acid group is significantly improved after 2 weeks of treatment. The blood glucose tolerance of the Gallic acid group after a treatment period of 2 weeks is also significantly better than that of the control group at 90 and 120 min ( p<0.05). The serum triglyceride concentration in the Gallic acid group (0.67±0.03 mM, p<0.05) is significantly reduced relative to that of the control group (1.08±0.20 mM). The total cholesterol concentration is similar in the control (3.19±0.27 mM) and Gallic acid (3.01±0.18 mM) groups ^[2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Appearance

Solid

Source

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL ( 265.77 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	5.3155 mL	26.5774 mL	53.1547 mL
5 mM	1.0631 mL	5.3155 mL	10.6309 mL
10 mM	0.5315 mL	2.6577 mL	5.3155 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.5 mg/mL (13.29 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (13.29 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.5 mg/mL (13.29 mM); Clear solution

* All of the co-solvents are available by MCE.

References

Synonyms

Benzoic acid, 3,4,5-trihydroxy-, hydrate (1:1)

Gallic acid, monohydrate

Benzoic acid, 3,4,5-trihydroxy-, monohydrate

3,4,5-Trihydroxybenzoic acid hydrate (1:1)